Современные достижения и проблемы в терапии первичного гипотиреоза

В статье представлен обзор современных подходов и проблем в ведении пациентов с первичным гипотиреозом. В настоящее время во всем мире проводятся многочисленные доклинические и клинические исследования, направленные на совершенствование заместительной терапии и на улучшение качества жизни пациентов с первичным гипотиреозом. Целью данного обзора явился анализ мировых исследований, проведенных за последние 5 лет, и современной литературы о новых возможностях и подходах к лечению первичного гипотиреоза. Для реализации цели был проведен систематический поиск в базе данных PubMed с использованием следующих ключевых слов: «primary hypothyroidism treatment», «levothyroxine side effects», «primary hypothyroidism outcome», «new approaches to hypothyroidism therapy», «new formulations of levothyroxine», «hypothyroidism in elderly» за период с 2018 по 2023 г. На основании данного анализа удалось сделать выводы о том, что изучение различных особенностей течения заболевания и поиск новых методов лечения актуален и должен проводиться, несмотря на кажущуюся легкость в проведении заместительной терапии.

1. Трошина Е.А., Платонова Н.М., Панфилова Е.А. Аналитический обзор результатов мониторинга основных эпидемиологических характеристик йододефицитных заболеваний у населения Российской Федерации за период 2009–2018 гг. Проблемы эндокринологии. 2021;67(2):10–19. DOI: 10.14341/probl12433

2. Гипотиреоз: МКБ 10: Е03.1–Е03.5/Е03.8/Е03.9/Е89.0/Е06.3: Министерство Здравоохранения Российской Федерации, Российская ассоциация эндокринологов. Москва. 2021:34. Текст: электронный. Рубрикатор клинических рекомендаций МЗ РФ. URL: https://cr.minzdrav.gov.ru/recomend/531_3 (Дата обращения 25.07.2023).

3. Мануйлова Ю.А., Моргунова Т.Б., Фадеев В.В. Причины неэффективности заместительной терапии первичного гипотиреоза. Клиническая и экспериментальная тиреоидология. 2019;15(1):12–18. DOI: 10.14341/ket10163

4. Virili C., Antonelli A., Santaguida M., Benvenga S., Centanni M. Gastrointestinal Malabsorption of Thyroxine. Endocrine. Review. 2019;40:118–136. DOI: 10.1210/er.2018-00168

5. Freeman M.K., Adunlin G.A., Mercadel C., Danzi S., Klein I. Hypothyroid symptoms in levothyroxine-treated patients. Innovation pharmacy. 2019;10(3):10.24926/iip.v10i3.2026. DOI: 10.24926/iip.v10i3.2026

6. Romero-Gómez B., Guerrero-Alonso P., Carmona-Torres J.M., Notario-Pacheco B., Cobo-Cuenca A.I. Mood disorders in levothyroxine-treated hypothyroid women. Int. J. Environ. Res. Public. Health. 2019;16(23):4776. DOI: 10.3390/ijerph16234776

7. Ruíz-Pacheco M.G., Hernández I., Hernández-Estrella G., Basurto L., Vargas-Ortega G., González-Virla B., Molina-Ayala M., Hernández-Martínez A.F., Luengas-Mondragón R., Hernández-Allende A.A., Mendoza-Zubieta V., Balcázar-Hernández L. Severity of fatigue and its relationship with tsh before and after levothyroxine replacement therapy in patients with primary hypothyroidism. Biomedicines. 2023;11(3):811. DOI: 10.3390/biomedicines11030811

8. Romero-Gómez B., Guerrero-Alonso P., Carmona-Torres J.M., Laredo-Aguilera J.A., Pozuelo-Carrascosa D.P., Cobo-Cuenca A.I. Sexual function in levothyroxine-treated hypothyroid women and women without hypothyroidism: a case-control. Int. J. Environ. Res. Public. Health. 2020;17(12):4325. DOI: 10.3390/ijerph17124325

9. Jansen H.I., Boelen A., Heijboer A.C., Bruinstroop E., Fliers E. Hypothyroidism: The difficulty in attributing symptoms to their underlying cause. Front. Endocrinol. (Lausanne). 2023;14:1130661. DOI: 10.3389/fendo.2023.1130661

10. Cui Z., Ding X., Bian N., Chang X., Wang J., An Y., Liu J., Wang G. Relatively lower FT3 levels are associated with impaired quality of life in levothyroxine-treated patients with hashimoto thyroiditis. Int. J. Endocrinol. 2022;2022:1918674. DOI: 10.1155/2022/1918674

11. Perros P., Nagy E.V., Papini E., Van Der Feltz-Cornelis C.M., Weetman A.P., Hay H.A., Abad-Madroñero J., Tallett A.J., Bilas M., Lakwijk P., Poots A.J., Hegedüs L. Hypothyroidism and somatization: results from e-mode patient self-assessment of thyroid therapy, a cross-sectional, international online patient survey. Thyroid. 2023;3. DOI: 10.1089/thy.2022.0641

12. Groenewegen K.L., Mooij C.F., van Trotsenburg A.S.P. Persisting symptoms in patients with Hashimoto’s disease despite normal thyroid hormone levels: Does thyroid autoimmunity play a role? A systematic review. J. Transl. Autoimmun. 2021;4:100101. DOI: 10.1016/j.jtauto.2021.100101

13. Perros P., Van Der Feltz-Cornelis C., Papini E., Nagy E.V., Weetman A.P., Hegedüs L. The enigma of persistent symptoms in hypothyroid patients treated with levothyroxine: A narrative review. Clin. Endocrinol. (Oxf). 2023;98(4):461–468. DOI: 10.1111/cen.14473

14. Díez J.J., Iglesias P. Control of thyroid dysfunction in spanish population registered in the primary care clinical database: an analysis of the proportion of patients with thyrotropin values outside the reference range. Horm. Metab. Res. 2023;55(3):184–190. DOI: 10.1055/a-2014-4589

15. Lee K.W., Shin Y., Lee S., Lee S. Inherited disorders of thyroid hormone metabolism defect caused by the dysregulation of selenoprotein expression. Front. Endocrinol. (Lausanne). 2022;12:803024. DOI: 10.3389/fendo.2021.803024

16. van Geest F.S., Groeneweg S., Visser W.E. Monocarboxylate transporter 8 deficiency: update on clinical characteristics and treatment. Endocrine. 2021;71(3):689–695. DOI: 10.1007/s12020-020-02603-y

17. Park E., Jung J., Araki O., Tsunekawa K., Park S.Y., Kim J., Murakami M., Jeong S.Y., Lee S. Concurrent TSHR mutations and DIO2 T92A polymorphism result in abnormal thyroid hormone metabolism. Sci. Rep. 2018;8(1):10090. DOI: 10.1038/s41598-018-28480-0

18. Mele C., Tagliaferri M.A., Pagano L., Soranna D., Scacchi M., Aimaretti G., Biondi B., Marzullo P. Levothyroxine replacement in obese adults: the role of metabolic variables and aging on thyroid testing abnormalities. J. Clin. Endocrinol. Metab. 2019;104(12):6265–6274. DOI: 10.1210/jc.2019-00773

19. Laclaustra M., Moreno-Franco B., Lou-Bonafonte J.M., Mateo-Gallego R., Casasnovas J.A., Guallar-Castillon P., Cenarro A., Civeira F. Impaired sensitivity to thyroid hormones is associated with diabetes and metabolic syndrome. Diabetes Care. 2019;42(2):303–310. DOI: 10.2337/dc18-1410

20. Sun Y., Teng D., Zhao L., Shi X., Li Y., Shan Z., Teng W. Impaired sensitivity to thyroid hormones is associated with hyperuricemia, obesity, and cardiovascular disease risk in subjects with subclinical hypothyroidism. Thyroid. 2022;32(4):376–384. DOI: 10.1089/ thy.2021.0500

21. Hoermann R., Midgley J.E.M., Larisch R., Dietrich J.W. Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options. Drugs Context. 2019;8:212597. DOI: 10.7573/dic.212597

22. Cruz-Loya M., Chu B.B., Jonklaas J., Schneider D.F., DiStefano J. 3rd. Optimized Replacement T4 and T4+T3 Dosing in male and female hypothyroid patients with different bmis using a personalized mechanistic model of thyroid hormone regulation dynamics. Front. Endocrinol. (Lausanne). 2022;13:888429. DOI: 10.3389/fendo.2022.888429

23. Zaborek N.A., Cheng A., Imbus J.R., Long K.L., Pitt S.C., Sippel R.S, Schneider D.F. The optimal dosing scheme for levothyroxine after thyroidectomy: A comprehensive comparison and evaluation. Surgery. 2019;165(1):92–98. DOI: 10.1016/j.surg.2018.04.097

24. Cruz-Loya M., Chu B.B., Jonklaas J., Schneider D.F., DiStefano J. 3rd. Optimized Replacement T4 and T4+T3 Dosing in male and female hypothyroid patients with different bmis using a personalized mechanistic model of thyroid hormone regulation dynamics. Front. Endocrinol. (Lausanne). 2022;13:888429. DOI: 10.3389/fendo.2022.888429

25. Gonzales K.M., Stan M.N., Morris J.C. 3rd., Bernet V., Castro M.R. The levothyroxine absorption test: a four-year experience (2015–2018) at The Mayo Clinic. Thyroid. 29(12):1734–1742. DOI: 10.1089/thy.2019.0256

26. Santos Monteiro S., Santos T.S., Lopes A.M., Oliveira J.C., Freitas C., Couto Carvalho A. Levothyroxine malabsorption or pseudomalabsorption? A question in the management of refractory hypothyroidism. Endocr. Connect. 2022;11(12):e220355. DOI: 10.1530/EC-22-0355

27. Bellastella G., Caputo M., Maiorino M.I., Longo M., Scappaticcio L., Giugliano D., Esposito K. EMPATHY: A new tool for identifying the most suitable thyroxine formulation in hypothyroid patients. Thyroid. 2019;29(7):928–933. DOI: 10.1089/thy.2018.0493

28. Tanguay M., Girard J., Scarsi C., Mautone G., Larouche R. Pharmacokinetics and comparative bioavailability of a levothyroxine sodium oral solution and soft capsule. Clin. Pharmacol. Drug Dev. 2019;8(4):521–528. DOI: 10.1002/cpdd.608

29. Bornikowska K., Gietka-Czernel M., Raczkiewicz D., Glinicki P., Zgliczyński W. Improvements in quality of life and thyroid parameters in hypothyroid patients on ethanol-free formula of liquid levothyroxine therapy in comparison to tablet LT4 form: an observational study. J. Clin. Med. 2021;10(22):5233. DOI: 10.3390/jcm10225233

30. Virili C., Giovanella L., Fallahi P., Antonelli A., Santaguida M.G., Centanni M., Trimboli P. Levothyroxine therapy: changes of TSH levels by switching patients from tablet to liquid formulation. a systematic review and meta-analysis. Front. Endocrinol. (Lausanne). 2018;9:10. DOI: 10.3389/fendo.2018.00010

31. Cherella C.E., Wassner A.J. Update on congenital hypothyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 2020;27(1):63–69. DOI: 10.1097/MED.0000000000000520

32. Guglielmi R., Grimaldi F., Negro R., Frasoldati A., Misischi I., Graziano F., Cipri C., Guastamacchia E., Triggiani V., Papini E. Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients. Endocr. Metab. Immune Disord Drug. Targets. 2018;18(3):235–240. DOI: 10.2174/1871530318666180125155348

33. Gatta E., Bambini F., Buoso C., Gava M., Maltese V., Anelli V., Delbarba A., Pirola I., Cappelli C. Liquid levothyroxine formulations in patients taking drugs interfering with L-T4 absorption. Front. Endocrinol. (Lausanne). 2022;13:1080108. DOI: 10.3389/fendo.2022.1080108. PMID: 36561558; PMCID: PMC9764388

34. Markantes G.K., Dimitropoulos K., Mamali I., Tseti I., Sakellaropoulos G., Markou K.B., Michalaki M.A. Therapeutic equivalence of a new preparation of liquid levothyroxine with tablets in patients with overt primary hypothyroidism. Eur. Thyroid. J. 2021;10(1):59–64. DOI: 10.1159/000508216

35. Fallahi P., Ferrari S.M., Elia G., Ragusa F., Paparo S.R., Antonelli A. L-T4 Therapy in enteric malabsorptive disorders. Front. Endocrinol. (Lausanne). 2021;12:626371. DOI: 10.3389/fendo.2021.626371

36. Virili C., Capriello S., Stramazzo I., Brusca N., Santaguida M.G., Gargano L., Bagaglini M.F., Bruno G., Severi C., Centanni M. Daily requirement of softgel thyroxine is independent from gastric juice pH. Front. Endocrinol. (Lausanne). 2022;13:1002583. DOI: 10.3389/fendo.2022.1002583

37. Liu H., Li W., Zhang W., Sun S., Chen C. Levothyroxine: conventional and novel drug delivery formulations. Endocr. Rev. 2023;44(3):393–416. DOI: 10.1210/endrev/bnac030

38. Vardarli I., Brandenburg T., Hegedüs L., Attanasio R., Nagy E., Papini E., Perros P., Weidemann F., Herrmann K., Führer D. A Questionnaire survey of german thyroidologists on the use of thyroid hormones in hypothyroid and euthyroid patients: the THESIS (treatment of hypothyroidism in europe by specialists: an international survey) collaborative. Exp. Clin. Endocrinol. Diabetes. 2022;130(9):577–586. DOI: 10.1055/a-1832-0644

39. Naman A., Delemer B., Marot D., Michelet E., Decoudier B., Barraud S. Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report. Medicine (Baltimore). 2022;101(26):e29690. DOI: 10.1097/MD.0000000000029690

40. Ritter M.J., Gupta S., Hennessey J.V. Alternative routes of levothyroxine administration for hypothyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 2020;27(5):318–322. DOI: 10.1097/MED.0000000000000558

41. Ghazi R.F., Al-Mayahy M.H. Levothyroxine sodium loaded dissolving microneedle arrays for transdermal delivery. ADMET DMPK. 2022;10(3):213–230. DOI: 10.5599/admet.1317

42. Levothyroxine. RxList. [Electronic resource]. URL: https://www. rxlist.com/levothyroxine/generic-drug.htm (Date of reference: 09.09.2023).

43. L-тироксин аналоги. VIDAL. [Электронный ресурс]. URL: https://www.vidal.ru/drugs/l-thyroxin__23557/analogs (Дата обращения 09.09.2023) [L-thyroxine analogues. VIDAL. [Electronic resource]. URL: https://www.vidal.ru/drugs/l-thyroxin__23557/ analogs (Date of reference: 09.09.2023)].

44. Peterson S.J., Cappola A.R., Castro M.R. et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2018;28(6):707–721. DOI: 10.1089/thy.2017.0681

45. Michaelsson L.F., la Cour J.L., Medici B.B. et al. Levothyroxine/liothyronine combination therapy and quality of life: is it all about weight loss? Eur. Thyroid. J. 2018;7(5):243–250. DOI: 10.1159/000490383

46. Bjerkreim B.A., Hammerstad S.S., Gulseth H.L., Berg T.J., Omdal L.J., Lee-Ødegård S., Eriksen E.F. Effect of liothyronine treatment on quality of life in female hypothyroid patients with residual symptoms on levothyroxine therapy: a randomized crossover study. Front. Endocrinol. (Lausanne). 2022;13:816566. DOI: 10.3389/fendo.2022.816566

47. Hughes D.A., Skiadas K., Fitzsimmons D., Anderson P., Heald A. Liothyronine for hypothyroidism: a candidate for disinvestment or in need of further research? A value of information analysis. BMJ Open. 2021;11(12):e051702. DOI: 10.1136/bmjopen-2021-051702

48. Latteyer S., Christoph S., Theurer S., Hönes GS., Schmid KW., Führer D., Moeller LC. Thyroxine promotes lung cancer growth in an orthotopic mouse model. Endocr. Relat. Cancer. 2019;26(6):565 – 574. DOI: 10.1530/ERC-18-0353

49. Wu C.C., Islam M.M., Nguyen P.A., Poly T.N., Wang C.H., Iqbal U., Li Y.J., Yang H.C. Risk of cancer in long-term levothyroxine users: Retrospective population-based study. Cancer. Sci. 2021;112(6):2533–2541. DOI: 10.1111/cas.14908

50. Alotaibe H.F., Alolaiwi L.A., Almutairi A., Alsubaie N., Badri M., Balaha M.F., Khafagy E.S., Alotaibi H.F. Association between levothyroxine replacement therapy and osteoporosis in Riyadh, Saudi Arabia: a matched case-control study. Pharmazie. 2022;77(10):295–298. DOI: 10.1691/ph.2022.2436

51. Lin S.Y., Lin C.L., Chen H.T., Kao C.H. Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study. Curr. Med. Res. Opin. 2018;34(5):805–812. DOI: 10.1080/03007995.2017.1378174

52. Kwak D., Ha J., Won Y., Kwon Y., Park S. Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMJ Open. 2021;11(5):e043007. DOI: 10.1136/bmjopen-2020-043007

53. Ku E.J., Yoo W.S., Lee E.K., Ahn H.Y., Woo S.H., Hong J.H., Chung H.K., Park J.W. Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2021;106(12):3655–3667. DOI: 10.1210/clinem/dgab539

54. Yu H., Zhang W., Shen C., Zhang H., Zhang H., Zhang Y., Zou D., Gong X. Liver dysfunction induced by Levothyroxine Sodium Tablets (Euthyrox®) in a hypothyroid patient with Hashimoto’s thyroiditis: case report and literature review. Endocr. J. 2019;66(9):769–775. DOI: 10.1507/endocrj.EJ19-0078

55. Einfeldt M.N., Olsen A.S., Kristensen S.L., Khalid U., Faber J., Torp-Pedersen C., Gislason G.H., Selmer C. Long-term outcome in patients with heart failure treated with levothyroxine: an observational nationwide cohort study. J. Clin. Endocrinol. Metab. 2019;104(5):1725–1734. DOI: 10.1210/jc.2018-01604

56. Mohajer B., Moradi K., Guermazi A., Mammen J.S.R., Hunter D.J., Roemer F.W., Demehri S. Levothyroxine use and longitudinal changes in thigh muscles in at-risk participants for knee osteoarthritis: preliminary analysis from Osteoarthritis Initiative cohort. Arthritis Res. Ther. 2023;25(1):58. DOI: 10.1186/s13075-023-03012-y

57. Nagy EV., Perros P., Papini E., Katko M., Hegedüs L. New formulations of levothyroxine in the treatment of hypothyroidism: trick or treat? Thyroid. 2021;31(2):193–201. DOI: 10.1089/thy.2020.0515

58. Stott D.J., Rodondi N., Kearney P.M., Ford I., Westendorp R.G.J., Mooijaart S.P., Sattar N., Aubert C.E., Aujesky D., Bauer D.C., Baumgartner C., Blum M.R., Browne J.P., Byrne S., Collet T.H., Dekkers O.M., den Elzen W.P.J., Du Puy R.S., Ellis G., Feller M., Floriani C., Hendry K., Hurley C., Jukema J.W., Kean S., Kelly M., Krebs D., Langhorne P., McCarthy G., McCarthy V., McConnachie A., McDade M., Messow M., O’Flynn A., O’Riordan D., Poortvliet R.K.E., Quinn TJ., Russell A., Sinnott C., Smit J.W.A., Van Dorland H.A., Walsh K.A., Walsh E.K., Watt T., Wilson R., Gussekloo J; TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N. Engl. J. Med. 2017;376(26):2534–2544. DOI: 10.1056/NEJMoa1603825

59. Gencer B., Moutzouri E., Blum M.R., Feller M., Collet T.H., Delgiovane C., da Costa B.R., Buffle E., Monney P., Gabus V., Müller H., Sykiotis G.P., Kearney P., Gussekloo J., Westendorp R., Stott D.J., Bauer D.C., Rodondi N. The impact of levothyroxine on cardiac function in older adults with mild subclinical hypothyroidism: a randomized clinical trial. Am. J. Med. 2020;133(7):848–856. e5. DOI: 10.1016/j.amjmed.2020.01.018

60. Zijlstra L.E., Jukema J.W., Westendorp R.G.J., Du Puy R.S., Poortvliet R.K.E., Kearney P.M., O’Keeffe L., Dekkers O.M., Blum M.R., Rodondi N., Collet T.H., Quinn T.J., Sattar N., Stott D.J., Trompet S., den Elzen W.P.J., Gussekloo J., Mooijaart S.P. Levothyroxine treatment and cardiovascular outcomes in older people with subclinical hypothyroidism: pooled individual results of two randomised controlled trials. Front. Endocrinol. (Lausanne). 2021;12:674841. DOI: 10.3389/fendo.2021.674841

61. Wildisen L., Feller M., Del Giovane C., Moutzouri E., Du Puy R.S., Mooijaart S.P., Collet T.H., Poortvliet R.K.E., Kearney P., Quinn T.J., Klöppel S., Bauer D.C., Peeters R.P., Westendorp R., Aujesky D., Gussekloo J., Rodondi N. Effect of levothyroxine therapy on the development of depressive symptoms in older adults with subclinical hypothyroidism: an ancillary study of a randomized clinical trial. JA-MA Netw. Open. 2021;4(2):e2036645. DOI: 10.1001/jamanetworkopen.2020.36645

62. Liu Y.S., Wei M., Wang L., Liu G., Ma G.P., Ono K., Cao Z.L., Yang M., Zheng M.Q. The impact of subclinical hypothyroidism on long-term outcomes in older patients undergoing percutaneous coronary intervention. BMC Endocr. Disord. 2021;21(1):43. DOI: 10.1186/s12902-021-00702-z

63. Pyun J.M., Park Y.H., Kim S. Subclinical hypothyroidism and cognitive impairment. J. Alzheimers Dis. 2022;88(2):757–762. DOI: 10.3233/JAD-220302

64. van Vliet N.A., van Heemst D., Almeida O.P., Åsvold B.O., Aubert C.E., Bae J.B., Barnes L.E., Bauer D.C., Blauw G.J., Brayne C., Cappola A.R., Ceresini G., Comijs H.C., Dartigues J.F., Degryse J.M., Dullaart R.P.F., van Eersel M.E.A., den Elzen W.P.J., Ferrucci L., Fink H.A., Flicker L., Grabe H.J., Han J.W., Helmer C., Huisman M., Ikram M.A., Imaizumi M., de Jongh R.T., Jukema J.W., Kim K.W., Kuller L.H., Lopez O.L., Mooijaart S.P., Moon J.H., Moutzouri E., Nauck M., Parle J., Peeters R.P., Samuels M.H., Schmidt C.O., Schminke U., Slagboom P.E., Stordal E., Vaes B., Völzke H., Westendorp R.G.J., Yamada M., Yeap B.B., Rodondi N., Gussekloo J., Trompet S; Thyroid studies collaboration. association of thyroid dysfunction with cognitive function: an individual participant data analysis. JAMA Intern. Med. 2021;181(11):1440–1450. DOI: 10.1001/jamainternmed.2021.5078

65. Du Puy R.S., Poortvliet R.K.E., Mooijaart S.P., Stott D.J., Quinn T., Sattar N., Westendorp R.G.J., Kearney P.M., McCarthy V.J.C., Byrne S., Rodondi N., Baretella O., Collet T.H., van Heemst D., Dekkers O.M., Jukema J.W., Smit J.W.A., Gussekloo J., den Elzen W.P.J. No effect of levothyroxine on hemoglobin in older adults with subclinical hypothyroidism: pooled results from 2 randomized controlled trials. J. Clin. Endocrinol. Metab. 2022;107(6):e2339–e2347. DOI: 10.1210/clinem/dgac106

66. Guan B., Luo J., Huang X., Tian F., Sun S., Ma Y., Yu Y., Liu R., Cao J., Fan L. Association between thyroid hormone levels and frailty in the community-dwelling oldest-old: a cross-sectional study. Chin. Med. J. (Engl). 2022;135(16):1962–1968. DOI: 10.1097/CM9.0000000000002208

67. Ravensberg A.J., Poortvliet R.K.E., Du Puy R.S., Dekkers O.M., Mooijaart S.P., Gussekloo J. Effects of discontinuation of levothyroxine treatment in older adults: protocol for a self-controlled trial. BMJ Open. 2023;13(4):e070741. DOI: 10.1136/bmjopen-2022-070741